Turnover—
EBIT margin—
Net result€-342k
Working capital€136k
Directors1
Conclusion
the dossier summarised in one paragraphA bankruptcy procedure is open for Amalus Therapeutics according to publications in the Belgian State Gazette. The 2024 annual accounts show negative equity (€-332k) and a net result of €-342k.
Based on the State Gazette, CBE and 1 annual account.
Bankruptcy probability (12 mo)
Checked model v1 · free for everyoneBankruptcy opened
A bankruptcy procedure is already open — a probability score is no longer meaningful. See the insolvency timeline for the state of the procedure.
Insolvency timeline
1 events10-03-2026
Bankruptcy
Opening
Financials
FY 2024
€-332k
equity
Turnover—
Net result€-342kHealth0/100 · Critical
See full annual accounts
People & board
No director data processed yet.
To directors Publicationslatest 10-03-2026
1
publications in the State GazetteAll publications & acts Network & structure
No network or structure data processed.
To structure
Trust signals
2 signalsYoung company
Founded in 2023 — under 3 years, statistically higher risk.
Open bankruptcy
Active bankruptcy procedure in the Belgisch Staatsblad. Claims are handled by the appointed curator.
Administrative Flags
0 events
No administrative flags
Company registry (CBE)
Crossroads BankActivities
Vervaardiging van farmaceutische grondstoffen21100Vervaardiging van farmaceutische grondstoffen21100Vervaardiging van geneesmiddelen21201Vervaardiging van geneesmiddelen21201Speur- en ontwikkelingswerk op biotechnologisch gebied72101Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied72109Speur- en ontwikkelingswerk op biotechnologisch gebied72110Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied72190
Primary activity highlighted.
Names & trade names
| Legal nameNL | Amalus Therapeutics |
Registered office
Technologiepark-Zwijnaarde 82
9052 Gent, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.